Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet-activating factor antagonists

J M Negro Alvarez1, J C Miralles López, J L Ortiz Martínez

  • 1Allergology Section, H. U. Virgen de la Arrixaca, El Palmar, Murcia, Spain.

Allergologia Et Immunopathologia
|December 12, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dupilumab to induce tolerance to SLIT-Melocotón®.

European annals of allergy and clinical immunology·2023
Same author

Effectiveness of Benralizumab in Severe Eosinophilic Asthma Under Conditions of Routine Clinical Practice.

Journal of investigational allergology & clinical immunology·2022
Same author

Quality of life in severe asthmatic patients treated with benralizumab.

European annals of allergy and clinical immunology·2021
Same author

Severe Asthma Units Accredited by the Spanish Society of Allergology and Clinical Immunology (SEAIC): Experience and Future.

Journal of investigational allergology & clinical immunology·2020
Same author

Benralizumab in Real Life.

Journal of investigational allergology & clinical immunology·2020
Same author

An Unusual Case of Contact Dermatitis to Vulcanization Additives.

Journal of investigational allergology & clinical immunology·2016
Same journal

Peach sublingual immunotherapy for lipid transfer protein syndrome.

Allergologia et immunopathologia·2026
Same journal

Gastrointestinal stenosis: an underrecognized complication of CARMIL2 deficiency.

Allergologia et immunopathologia·2026
Same journal

Peach sublingual immunotherapy for lipid transfer protein syndrome.

Allergologia et immunopathologia·2026
Same journal

Vitamin B12 allergy and desensitization.

Allergologia et immunopathologia·2026
Same journal

Chronic HBV infection, stemness pathways, and compromised immune surveillance in HCC development.

Allergologia et immunopathologia·2026
Same journal

Application of FeNO in the diagnostic and therapeutic algorithm of pediatric asthma: From chronic cough and wheeze to personalized management.

Allergologia et immunopathologia·2026
See all related articles

Platelet-activating factor (PAF) antagonists, including natural and synthetic compounds, are being developed for various conditions. Research is ongoing, with many PAF antagonists in early development stages, showing therapeutic potential.

Area of Science:

  • Pharmacology and Drug Development
  • Inflammation and Immunology

Background:

  • Platelet-activating factor (PAF) is a potent pro-inflammatory mediator produced by various cell types.
  • The chemical structure of PAF has been identified, leading to the development of numerous specific receptor antagonists.

Purpose of the Study:

  • To review the most important PAF receptor antagonists, both natural and synthetic.
  • To assess the effectiveness of these antagonists in various experimental tests.
  • To provide an overview of the development status of PAF receptor antagonists.

Main Methods:

  • Comprehensive literature search of Medline and Embase databases (1966-1996).
  • Inclusion of English-language articles, clinical trial research, review articles, and conference abstracts.
  • Identification and categorization of natural and synthetic PAF receptor antagonists.

Related Experiment Videos

Main Results:

  • A large variety of PAF receptor antagonists, natural and synthetic, have been described.
  • These antagonists exhibit significant variability in chemical structure, potentially influencing their pharmacological profiles.
  • The majority of identified PAF antagonists are still under development, with only a few having progressed to clinical trials.

Conclusions:

  • PAF antagonists represent a diverse group of compounds with potential therapeutic applications.
  • Ongoing research and development by pharmaceutical companies highlight the therapeutic interest in targeting PAF receptors.
  • Further investigation and clinical trials are necessary to determine the efficacy and safety of these antagonists.